Joel Lexchin, M.D., from York University in Toronto, reports that 71 drugs approved by the FDA from 2002 to 2014 for solid tumors have resulted in median gains in progression-free and overall survival of 2.5 and 2.1 months, respectively. He also points out that a similar study of solid cancer drugs within 10 years of EMA approval improved survival by slightly over a month.
Poll Question:
Do you think regulatory agencies should be required to provide stronger evidence of the clinical effectiveness of cancer drugs, including a greater emphasis on patient survival time?
Yes
79
No
10
